Novo Nordisk (NVO) Stock Rockets 6% Following FDA’s Compounding Pharmacy Crackdown

TLDR

• Shares of Novo Nordisk rallied more than 6% following FDA’s proposal to remove semaglutide, tirzepatide, and liraglutide from the 503B compounding bulks list
• The regulatory agency stated no medical necessity exists for outsourcing facilities to compound these medications
• Public feedback will be accepted through June 29, 2026, prior to the final ruling
• NVO reached its strongest price point in over sixty days, leading Copenhagen’s exchange on Thursday
• Despite Thursday’s rally, shares remain more than 16% lower year-to-date

Shares of Novo Nordisk soared over 6% during Thursday’s trading session following the FDA’s announcement of proposed restrictions on weight-loss medication compounding—a regulatory shift that stands to significantly benefit the Danish pharmaceutical giant.

Novo Nordisk A/S, NVO

The Food and Drug Administration unveiled plans to eliminate semaglutide, tirzepatide, and liraglutide from the 503B bulks list. According to the agency, outsourcing facilities have no legitimate clinical justification for compounding these specific drugs.

The pharmaceutical company’s shares climbed to their strongest level in more than sixty days during Thursday’s session, claiming the top spot among gainers on Copenhagen’s stock exchange.

NVO was changing hands at approximately $42.38 during recent trading, substantially higher than its 20-day moving average of $39.03 and comfortably above its 50-day moving average of $38.87.

Even with Thursday’s impressive gains, the stock continues trading beneath its 200-day moving average of $50.32 and remains more than 16% lower for the year.

The FDA has initiated a public consultation window extending through June 29, 2026, before finalizing any decision regarding the proposed regulations.

What’s Weighing on Novo Nordisk

Novo Nordisk has encountered several challenges in recent months. Canadian health authorities granted approval for the first biosimilar version of Ozempic in Canada, introducing fresh competitive pressures in a critical market.

The company responded by implementing a stock repurchase initiative. Approximately 13.4 million B-shares have been bought back for 3.44 billion Danish kroner since February 2026, forming part of a broader 15 billion kroner, twelve-month repurchase strategy.

Regarding its development pipeline, the pharmaceutical firm has initiated a Phase 3 clinical study for a knee osteoarthritis therapy and secured FDA fast-track status for a cardiovascular medication.

First quarter 2026 financial results are set for release on May 6.

What the Technicals Say

Near-term momentum indicators reflect positive movement. The MACD indicator has generated a buy signal while the RSI registers 54.73, indicating moderately bullish conditions.

Nevertheless, the ADX measurement of 17.26 indicates the current trend is lacking substantial strength. The Stochastic RSI has triggered a sell signal, suggesting the stock has entered overbought territory.

Anton Kharitonov from Traders Union highlighted the delicate technical landscape, noting that weakening momentum signals and overbought conditions indicate purchasing pressure may diminish rapidly. He identified the generic Ozempic threat in Canada as an additional risk factor.

Viktoras Karapetjanc, also representing Traders Union, maintains a more optimistic perspective. He views the buyback initiative and robust clinical development pipeline as foundational support for long-term shareholder value, characterizing the recent decline as a possible springboard for future gains.

Market analyst Jainam Mehta identifies a critical trading zone between $40.78 and $43.23 as the primary area of focus. He noted that a convincing breach above or below these threshold levels would be necessary to alter the immediate-term risk assessment.

The stock began Thursday’s session with an upward gap of approximately $0.37 and advanced $1.94, representing a 4.80% intraday increase. Intraday price volatility measured 2.47%.